• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯巴比妥在遗传性肥胖的 Zucker 大鼠中的研究。I. 急性和慢性给药后的药代动力学。

Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration.

作者信息

Brouwer K L, Kostenbauder H B, McNamara P J, Blouin R A

出版信息

J Pharmacol Exp Ther. 1984 Dec;231(3):649-53.

PMID:6502518
Abstract

The pharmacokinetics of the enzyme inducer, phenobarbital, was evaluated in genetically obese and lean Zucker and lean Sprague-Dawley rats. The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter). Standardizing the volume of distribution for total body weight in the obese and lean Zucker and lean Sprague-Dawley rats resulted in similar volume terms. Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr). Greater differences in phenobarbital clearance were observed when clearance was corrected for body weight. Whether comparing the absolute or standardized pharmacokinetic data, lean and obese Zucker rats will exhibit 2- to 3-fold higher phenobarbital plasma concentrations after administration of a standard 75- to 100-mg/kg enzyme-inducing regimen relative to Sprague-Dawley rats. Pharmacokinetic parameters from the single dose study were used to calculate appropriate phenobarbital doses (21-58 mg/kg/12 hr) to achieve similar steady-state phenobarbital plasma concentrations after chronic oral administration in all three groups of rats. Steady-state phenobarbital clearance values were not significantly different from clearance values after single dose administration in each group of rats. The dramatic intra- and inter-strain alterations in phenobarbital disposition demonstrated in this study explain the high mortality reported in Zucker rats after administration of traditional enzyme induction doses of phenobarbital. Differences in phenobarbital disposition should be considered in enzyme induction studies.

摘要

在遗传性肥胖和瘦型的 Zucker 大鼠以及瘦型的 Sprague-Dawley 大鼠中评估了酶诱导剂苯巴比妥的药代动力学。苯巴比妥在肥胖 Zucker 大鼠中的分布容积更大(0.416 升),高于瘦型 Zucker 大鼠(0.299 升)或 Sprague-Dawley 大鼠(0.312 升)。将肥胖和瘦型 Zucker 大鼠以及瘦型 Sprague-Dawley 大鼠的分布容积按总体重进行标准化后,得到了相似的容积值。在肥胖和瘦型 Zucker 大鼠(分别为 11.9 和 14.1 毫升/小时)与瘦型 Sprague-Dawley 大鼠(23.0 毫升/小时)之间观察到了苯巴比妥清除率的种内和种间差异。当清除率按体重校正时,观察到苯巴比妥清除率的差异更大。无论比较绝对的还是标准化的药代动力学数据,相对于 Sprague-Dawley 大鼠,在给予标准的 75 至 100 毫克/千克酶诱导方案后,瘦型和肥胖 Zucker 大鼠的苯巴比妥血浆浓度将高出 2 至 3 倍。单剂量研究的药代动力学参数用于计算合适的苯巴比妥剂量(21 - 58 毫克/千克/12 小时),以便在三组大鼠长期口服给药后达到相似的苯巴比妥稳态血浆浓度。每组大鼠的苯巴比妥稳态清除率值与单剂量给药后的清除率值无显著差异。本研究中所展示的苯巴比妥处置的显著种内和种间改变解释了在给予传统酶诱导剂量的苯巴比妥后 Zucker 大鼠中报道的高死亡率。在酶诱导研究中应考虑苯巴比妥处置的差异。

相似文献

1
Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration.苯巴比妥在遗传性肥胖的 Zucker 大鼠中的研究。I. 急性和慢性给药后的药代动力学。
J Pharmacol Exp Ther. 1984 Dec;231(3):649-53.
2
Phenobarbital in the genetically obese Zucker rat. II. In vivo and in vitro assessments of microsomal enzyme induction.苯巴比妥对遗传性肥胖的 Zucker 大鼠的影响。II. 微粒体酶诱导的体内和体外评估。
J Pharmacol Exp Ther. 1984 Dec;231(3):654-9.
3
Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.过氧化物酶体增殖物激活受体激动剂在遗传性肥胖的 Zucker 大鼠和 Sprague-Dawley 大鼠体内的药代动力学差异:肥胖 Zucker 大鼠葡萄糖醛酸化降低的影响
Drug Metab Dispos. 2004 Sep;32(9):909-14.
4
Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent.苯巴比妥诱导与对乙酰氨基酚肝毒性:肥胖 Zucker 啮齿动物的抗性
J Pharmacol Exp Ther. 1987 Nov;243(2):565-70.
5
Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways.遗传性肥胖和苯巴比妥治疗对肝脏结合途径的影响。
J Pharmacol Exp Ther. 1993 Jun;265(3):1333-8.
6
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.(±)-维拉帕米在瘦型和肥胖型 Zucker 大鼠体内的药代动力学和动力学
J Pharmacol Exp Ther. 1986 Aug;238(2):642-7.
7
Acetaminophen hepatotoxicity: influence of phenobarbital and beta-naphthoflavone treatment in obese and lean Zucker rats.对乙酰氨基酚肝毒性:苯巴比妥和β-萘黄酮处理对肥胖和瘦型 Zucker 大鼠的影响
Toxicol Appl Pharmacol. 1993 Dec;123(2):219-25. doi: 10.1006/taap.1993.1240.
8
Cyclosporine disposition in the hyperlipidemic rat model.
Res Commun Chem Pathol Pharmacol. 1988 Mar;59(3):339-48.
9
Modulation of gluconeogenesis by epinephrine in hepatocytes isolated from genetically obese (fa/fa) Zucker rats.肾上腺素对遗传性肥胖(fa/fa) Zucker大鼠分离的肝细胞中糖异生的调节作用
Arch Biochem Biophys. 2000 Jan 1;373(1):249-54. doi: 10.1006/abbi.1999.1533.
10
Cytochrome P450 2B enzyme induction defect after 2,2',4,4',5,5'-hexachlorobiphenyl treatment in the fa/fa Zucker rat.
J Pharmacol Exp Ther. 1994 Mar;268(3):1565-70.

引用本文的文献

1
Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats.肥胖对清醒大鼠体内硝酸甘油药效学的影响。
AAPS PharmSci. 2002;4(4):E28. doi: 10.1208/ps040428.
2
Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.α干扰素单一疗法对癌症患者肝脏药物代谢的影响。
Br J Clin Pharmacol. 1993 Sep;36(3):229-35. doi: 10.1111/j.1365-2125.1993.tb04222.x.
3
Drug disposition in obese humans. An update.肥胖人群中的药物处置。最新进展。
Clin Pharmacokinet. 1986 May-Jun;11(3):199-213. doi: 10.2165/00003088-198611030-00002.
4
Modification of inflammatory processes by phenobarbital in rats.苯巴比妥对大鼠炎症过程的影响
Inflammation. 1991 Dec;15(6):471-80. doi: 10.1007/BF00923344.
5
Phenobarbital pharmacokinetics in obesity. A case report.肥胖患者中苯巴比妥的药代动力学。一例报告。
Clin Pharmacokinet. 1992 Jun;22(6):481-4. doi: 10.2165/00003088-199222060-00006.